Nima Sharifi
@nimasharifimd
Prostate Cancer Medical Oncologist & Scientific Director, Desai Sethi Urology Institute, Sylvester Cancer Center, University of Miami Miller School of Medicine
ID: 2921955274
http://nimasharifilab.com 14-12-2014 20:22:42
6,6K Tweet
4,4K Takipçi
987 Takip Edilen
First participant enrolled on the “Mobile PSA Screening Clinic & Community Health Cohort”— years in the making and a huge milestone for our innovative approach to research in the community with “precision outreach” Nima Sharifi Desai Sethi Urology Institute Sylvester Comprehensive Cancer Center
Nima Sharifi Duke Cancer One conclusion here is clearly that ADT alone is insufficient for mHSPC patients and an ARPI can rescue these poor outcomes, as really all genotype groups benefited. The differences in fracture rate and gynecomastia by genotype are really intriguing! DCI Center for Prostate & Urologic Cancers
Thank you Brian Rini, MD and Tom Powles for inviting me to discuss prostate cancer hormonal therapy resistance on Uromigos! podcasters.spotify.com/pod/show/the-u…
Six genes involved in androgen production/ uptake/ conversion (APUC) distinguish ligand-driven PCa from AR-driven PCa, and have unique clinical outcomes. Congrats to Justin Hwang and his team. Nima Sharifi Charles Ryan Caris Life Sciences insight.jci.org/articles/view/…
TY Emmanuel Antonarakis -Androgen production still has a lot to reveal- a target rich environment - The "APUC6" may be the key drivers of a high ligand production, low AR prostate cancer. More to follow...hopefully translation! congrats Hannah, JUstin and team Masonic Cancer Center, University of Minnesota Caris Life Sciences